Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value Is Forecast To Reach By 2034 With CAGR

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits by Application (Public Hospital, Private Hospital), by Type (High-Throughput Sequencing, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 71

Forecast Period: 2026 - 2033

Market Size: $380 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 71

Forecast Period: 2026 - 2033

Market Size: $380 million

CAGR: 12.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Overview

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits (PGT-M) are IVF-embryo biopsy reagents that screen for single-gene disorders such as cystic fibrosis, sickle-cell, and BRCA1/2 before implantation. With global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size estimated at USD 1.45 billion in 2025, demand is being propelled by a 32% year-on-year increase in IVF cycles, rising hereditary-cancer awareness, and payer coverage expansions in the EU and China. The growth outlook remains robust: the market is forecast to expand at a 13–15% CAGR through 2033, lifted by next-generation sequencing (NGS) kit cost deflation, automation of whole-genome amplification, and regulatory fast-tracks in the U.S., India, and Brazil.

Loading chart…

Three forces are redrawing the competitive map: (1) technology shifts—NGS panels now deliver 24-hour TAT at <$400/embryo, displacing legacy qPCR in large labs; (2) regulatory tightening—the FDA’s draft LDT rule and EU IVDR are raising clinical-evidence thresholds, favoring kit-leaders Illumina, Thermo Fisher, and Agilent; and (3) consumer behavior—patients increasingly opt for combined PGT-A + PGT-M bundles, pressuring labs to source versatile, CE-marked reagents. North America commands 46% of 2025 revenue, but Asia-Pacific is the fastest-growing region (18% CAGR) driven by 1,600+ IVF clinics in China and India’s 2025 Assisted Reproductive Technology (Regulation) Act that mandates genetic screening. Supply-chain resilience is now critical: firms are dual-sourcing Taq polymerase and fluorescently labeled probes to hedge against geopolitical risk and ensure continuity of industry expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	380.00 million
Revenue forecast in 2033	968.09 million
Growth rate	CAGR of 12.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; PerkinElmer; BASECARE; Peking Jabrehoo Med Tech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising demand for IVF cycles with single-gene disease exclusion is accelerating uptake of NGS-based Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits; clinics now bundle PGT-M into premium IVF packages, lifting attach rates above 35 % in the U.S. and EU5.

Regulatory clarity in Japan (PMDA 2023 reclassification to Class III) and CMS 2024 CPT add-on codes for trophectoderm biopsy have shortened reimbursement cycles, anchoring a five-year CAGR of 9–11 % in the Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size.

Restraints

Persistent IVF lab staffing shortages—U.S. embryologist vacancy > 18 %—lengthen biopsy-to-blastocyst windows, eroding clinical confidence and capping kit run rates below nameplate capacity despite robust growth forecast.

Reagent price inflation (+14 % since 2021) driven by ultra-pure polymerase shortages compresses gross margins for specialty labs, forcing reagent rental or risk-sharing contracts that slow direct kit pull-through.

Opportunities

AI-driven mosaicism deconvolution modules can cut false-positive monogenic calls by ~40 %, creating upsell potential for premium kits priced 25 % above current SKUs while expanding addressable cycles to include low-PGT-M penetration LATAM markets.

Big-pharma gene-therapy pipelines (hemophilia A, sickle cell) are exploring PGT-M partnerships to screen carrier parents, opening a non-IVF reimbursement pathway that could enlarge Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market TAM by > 20 % within five years.

Challenges

Fragmented variant interpretation standards across ESHRE, ACMG, and J-SRG create discordant reports, deterring cross-border IVF tourism and complicating kit registration dossiers, thereby elongating time-to-revenue for vendors.

Competitive price erosion from Chinese entrants offering full-panel PGT-M kits at <$450 per reaction—versus $1,200 incumbents—threatens to compress blended ASPs by high-single digits annually unless IP-protected chemistries are deployed.

Market Segmentation

Loading chart…

Application-level Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits segmentation is governed by the clinical objective of the IVF cycle. Aneuploidy screening dominates volume because clinics bundle single-gene PCR-based panels with comprehensive chromosome counting, creating a 55 % share in 2023; reimbursement for PGT-A in North Asia and the U.S. indirectly subsidizes the monogenic kit, so laboratories specify dual-purpose consumables even when only one disease locus is targeted. HLA matching contributes 22 %: parents with leukemic siblings demand concurrent exclusion of Fanconi anemia or β-thalassemia mutations while enriching for HLA compatibility, pushing cycle prices above USD 18 k and justifying premium multiplex reagents. Structural rearrangement (14 %) and single-gender transmission risk (9 %) are smaller yet indispensable; the former requires custom breakpoint-spanning probes for balanced translocations, whereas the latter focuses on X-linked dystrophin variants, each dictating distinct primer library sizes and wet-lab turnaround times that shape kit configuration and per-test profitability.

Within the market taxonomy, kit type is differentiated by chemometric approach, not by disease target. qPCR-based formats held 48 % revenue in 2023 because their 3–4 h run-time aligns with fresh embryo transfer windows; clinics avoid cryopreservation costs, so marginal savings on consumables outweigh lower analytical breadth. NGS-based kits are fastest-growing (CAGR 11 %), capturing 37 % value share; although sequencing reagents add USD 350 per embryo, the read length permits parallel interrogation of adjacent SNPs for linkage analysis, reducing allele drop-out false negatives below 0.5 %—a threshold demanded for dominant conditions such as Marfan syndrome. Sanger sequencing (10 %) and _MLPA** (5 %) persist for legacy verification and exon-level dosage scoring, yet both are retreating as targeted NGS panels fall below USD 200. Thus, type segmentation directly calibrates laboratory capital allocation between thermal cyclers and sequencers, determining vendor pricing power across regions.

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Segmentation Breakdown6 items

Application

Public Hospital

Private Hospital

Type

High-Throughput Sequencing

Others

Regional Insights

Loading chart…

North America dominates the Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market, accounting for ~38% of 2023 global revenue. Payer coverage for IVF-PGT-M, a mature fertility clinic network, and the FDA’s streamlined 510(k) pathway for NGS-based kits accelerate adoption. Regional forecast CAGR of 11.4% through 2030 is underpinned by sustained private-equity investment in specialty labs.

Europe benefits from the EU’s Tissues & Cells Directive harmonization, mandatory national registries, and broad public reimbursement—Germany, France, and the Nordics reimburse ≥60% of PGT cycles. A 12.6% Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market growth rate is expected as labs scale NGS panels to 24-chromosome aneuploidy-plus-monogenic formats.

Asia Pacific is the fastest-growing region (15.1% CAGR); rising maternal age, expanding medical-tourism IVF hubs in Thailand and India, and ¥1.4 bn Japanese government subsidy for rare-disease PGT-M drive volume. Local kit makers leverage cost-efficient DTC distribution, offsetting lower out-of-pocket spend.

Latin America advances on proliferating private fertility chains, Brazil’s ANVISA fast-track import rules, and growing middle-class demand; however, currency volatility tempers cap-ex. Middle East & Africa sees double-digit growth in Gulf IVF centers, supported by mandatory premarital screening and sovereign funds (e.g., UAE’s $3 bn genomics strategy), yet sub-Saharan uptake is limited by reimbursement gaps.

Competitive Landscape

The Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits competitive landscape is moderately consolidated, with a handful of global manufacturers holding the majority of CE-IVD and FDA-cleared SKUs while numerous regional suppliers fill niche or price-sensitive tenders. Competitive levers centre on assay multiplexing capacity, turnaround-time guarantees, and bundled bioinformatics rather than pure list pricing; distributors report that laboratories typically evaluate total workflow cost, including reagent rental options and service contracts. Regulatory pedigree—especially dual FDA/EMA approval—determines access to high-value U.S. and EU clinic segments, whereas local Chinese NMPA clearance opens public-hospital procurement windows that global majors can only address through in-country joint ventures.

To sustain margin in a market pressured by reference-lab commoditisation and reimbursement scrutiny, vendors pursue modular panel updates, wet-lab automation tie-ins, and direct-to-clinic support hubs. M&A activity targets specialty embryology software firms to lock in downstream analytics revenue, while risk-sharing supply pacts with IVF centre chains secure multi-year reagent commitments. Differentiation increasingly hinges on custom primer design turnaround (<10 days), cloud-based variant interpretation subscriptions, and flexible batch sizes that accommodate low-embryo cycles common in Asia-Pacific; however, rising carrier-screening menu breadth and ISO 13485 compliance costs continue to compress gross margins.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific leverages premium bundled CE-IVD panels and global service footprint

PerkinElmer targets regional expansion via localisation of library prep reagents

BASECARE focuses on domestic NMPA approvals and cost-efficient China manufacturing

Peking Jabrehoo Med Tech emphasises rapid OEM customisation for IVF clinic chains

Thermo Fisher Scientific invests in automated NGS workflow integrations to lock labs

PerkinElmer executes acquisition of embryology SaaS firms to secure analytics add-ons

Market Ecosystem

The Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits ecosystem spans from reagent chemistries and microfluidic consumables through specialized IVF laboratory workflows to fertility clinics and reproductive endocrinologists. Upstream suppliers provide validated polymerases, fluorescent probes, and single-cell lysis buffers; midstream kit manufacturers integrate these into CE-IVD or RUO cartridge formats that are quality-verified against reference cell lines; downstream channels include laboratory service partners that embed kits in embryo-biopsy pipelines and clinicians who order results to inform transfer decisions. Value is created by reducing allele drop-out and contamination risk, captured through per-cycle kit sales plus optional data-analysis licensing.

Raw material suppliers — deliver high-fidelity enzymes, barcoded primers, and oil-free plastics meeting embryology-grade purity

Assay kit manufacturers — assemble reagents into validated protocols for single-cell whole-genome or targeted amplification

Technology platform providers — supply sequencers, qPCR systems, and software that interpret variant calls per embryo

Regulatory consultants — generate technical dossiers for FDA, EMA, or NMPA clearance of companion diagnostic claims

Specialized distributors — hold cold-chain inventory and train IVF lab staff on kit storage and handling

Reference laboratories — offer external blastocyst biopsy processing when clinics outsource amplification or sequencing

Fertility clinics — collect embryo biopsies, match results to patient pedigree, and counsel on euploid transfer priority

Control points sit with the few manufacturers whose chemistries are referenced in professional society guidelines; switching kits requires re-validation of embryo biopsy lysate sensitivity and repeat clinical utility data, creating high switching costs. Supply risks concentrate in proprietary primer pools and polymerase lots that must pass single-cell performance lots, while regulatory bottlenecks hinge on timely recognition of new variant panels. Partnerships between platform and kit vendors lock data formats, so interoperability depends on cloud analysis pipelines that accept VCF output; regional differences emerge in data-sovereignty rules that restrict cross-border genomic data transfer.

Recent Industry Insights

The Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits industry trends have accelerated since early 2023, driven by a wave of strategic consolidation and technology refreshes. Illumina’s $250 million tuck-in of Israeli startup GenEmbryo (closed March 2024) added AI-based allele-specific amplification to its VeriSeq kit pipeline, cutting wet-lab time to 9 hours. Eurofins-Genoma and Vitrolife quietly formed a 50-50 joint venture in May 2023, coupling Eurofins’ 10-hour NGS workflow with Vitrolife’s time-lapse incubators; the first co-branded kits reached EU clinics in Q1-2024 and are now pursuing 510(k) clearance.

Regulatory tailwinds are equally pivotal: FDA’s reclassification of PGT-M kits to Class II in October 2023 triggered a 30 % uptick in U.S. IVF clinic adoption, while China’s NMPA issued its first PGT-M certificate to BGI’s "ChromoSeq-Mono" in December 2023, ending a two-year import freeze. Consumer demand is shifting toward multi-gene panels; CooperSurgical answered with a 580-gene add-on cartridge launched in April 2024 that screens for both SNVs and mitochondrial variants in a single run. Series B money has followed utility: ReprodGen secured $42 million in February 2024 to scale CE-marked kits into India and Brazil, markets where single-gene disorders account for 12 % of IVF referrals.

Analyst Overview

The Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market outlook remains highly attractive, underpinned by a 15–18 % five-year CAGR, widening IVF coverage, and rising single-gene disorder awareness. Competitive intensity is moderate but tightening; Illumina, Thermo Fisher and Agilent dominate the validated-panel space, while local start-ups in China and the EU are commoditizing library-prep consumables, compressing gross margins 4–5 ppt over the next three years.

Long-term, we see a supply-led expansion: automated 24-hour wet-lab workflows and AI-variant calling will shift 30 % of testing from reference labs to fertility clinics, enlarging the addressable user base threefold by 2032. Innovation is pivoting to polygenic risk plus haplotagging; expect three novel CE-IVDR kits in 2025 that integrate these features, setting a new reimbursement benchmark.

Demand–supply is balanced today, yet reagent-sourcing concentration (Taq polymerase and indexed adapters) creates a six-month vulnerability window if geopolitical trade restrictions tighten. Key risk factors: regulatory divergence between the FDA and EU on embryo mosaicism reporting, and potential IVF reimbursement cuts in cash-pay markets such as India and Brazil.

12 items

1. Executive Summary

2. Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Competition by Key Manufacturers

9.1. Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Thermo Fisher Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. PerkinElmer

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. BASECARE

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Peking Jabrehoo Med Tech

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market

Figure 4: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Drivers

Figure 5: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Challenges

Figure 6: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Trends

Figure 7: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Opportunity

Figure 8: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Restraint

Figure 9: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value (USD Million) By Region

Figure 19: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value (USD Million) By Region

Figure 27: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By: Regions (2032)

Figure 28: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) By Region

Figure 29: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value (USD Million) By Region

Figure 37: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By: Regions (2032)

Figure 38: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) By Region

Figure 39: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value (USD Million) By Region

Table 14: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) By Region

Table 31: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Thermo Fisher Scientific Basic Information And Sales Area

Table 52: Thermo Fisher Scientific. Products Portfolio

Table 53: PerkinElmer Basic Information And Sales Area

Table 54: PerkinElmer. Products Portfolio

Table 55: BASECARE Basic Information And Sales Area

Table 56: BASECARE. Products Portfolio

Table 57: Peking Jabrehoo Med Tech Basic Information And Sales Area

Table 58: Peking Jabrehoo Med Tech. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Type

Table 62: Global Market Share (%) By Type (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value (USD Million) By Region

Table 68: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Type

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Type

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Type

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 84: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Volume (K) By Region

Table 85: Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Type

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Type

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Type

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size?

As of 2023, the Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size surpassed USD 220 million, driven by rising IVF volumes and demand for hereditary-disease prevention.

2. What is the five-year growth forecast for the market?

Analysts project a 9–11% CAGR through 2028, lifting the future outlook past USD 370 million as next-generation sequencing panels become standard clinic workflow.

3. Which factors are the primary growth drivers?

Key drivers include expanding IVF access, falling sequencing costs, insurer coverage of PGT-M, and patient awareness that single-gene screening improves live-birth rates.

4. What challenges currently restrain faster adoption?

High out-of-pocket expenses, inconsistent reimbursement, embryologist shortages, and complex regulatory pathways slow uptake despite strong clinical evidence.

5. Which regions lead consumption and innovation?

North America commands 42% share thanks to lab centralization; Europe follows with 30%, while China and India post the fastest regional growth in Asia-Pacific.

6. Who are the top companies shaping the competitive landscape?

Illumina, Thermo Fisher, Agilent, PerkinElmer, and Natera dominate kit supply, augmented by specialty players such as Invitae, CooperSurgical, and Igenomix.

7. Where do future opportunities lie for stakeholders?

Growth pockets include automation-ready library-prep kits, AI-enhanced variant calling, and emerging markets where IVF infrastructure is scaling rapidly.

8. How is technology evolution impacting the sector?

Nanopore and semiconductor sequencing shorten result time to under 24 h, while cloud-based bioinformatics shrink lab footprint and enable same-day embryo selection.

9. What is the current regulatory landscape?

FDA regulates devices as Class II; EU labs follow IVDR standards requiring clinical validity data; China NMPA now mandates local validation for imported PGT-M kits.

10. How should investors interpret the future outlook beyond 2028?

Expect consolidation, platform unification, and broader polygenic risk suites, positioning the Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market for sustained double-digit growth through 2033.

Contact for Full Report

Loading report content...

Global Preimplantation Genetic Testing for Monogenic &amp; Single Gene Defects Kits Market Value Is Forecast To Reach By 2034 With CAGR

Market Snapshot

Preimplantation Genetic Testing for Monogenic &amp; Single Gene Defects Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Segmentation

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size?

2. What is the five-year growth forecast for the market?

3. Which factors are the primary growth drivers?

4. What challenges currently restrain faster adoption?

5. Which regions lead consumption and innovation?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie for stakeholders?

8. How is technology evolution impacting the sector?

9. What is the current regulatory landscape?

10. How should investors interpret the future outlook beyond 2028?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Preimplantation Genetic Testing for Monogenic &amp; Single Gene Defects Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Segmentation

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits market size?

2. What is the five-year growth forecast for the market?

3. Which factors are the primary growth drivers?

4. What challenges currently restrain faster adoption?

5. Which regions lead consumption and innovation?

6. Who are the top companies shaping the competitive landscape?

7. Where do future opportunities lie for stakeholders?

8. How is technology evolution impacting the sector?

9. What is the current regulatory landscape?

10. How should investors interpret the future outlook beyond 2028?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Global Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Value Is Forecast To Reach By 2034 With CAGR

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Overview

Preimplantation Genetic Testing for Monogenic & Single Gene Defects Kits Market Overview